• Home
  •  / Enanta Pharmaceuticals

Enanta Pharmaceuticals

  • Revenue$97.1 MFY, 2021
  • Market Capitalization$1.1 B2022-07-29

OverviewSuggest Edit

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on three disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV).

TypePublic
Founded1998
HQWatertown, MA, USMap
Websiteenanta.com
Employee Ratings3.8
Overall CultureFMore
View Jobs (25)

Locations

Enanta Pharmaceuticals is headquartered in
Watertown, United States

Location Map
All Locations (2)

Latest Updates

Employees (est.) (Sept 2019)132(+17%)
Job Openings25
Revenue (FY, 2021)$97.1 M(-52%)
Share Price (Jul 2022)$55.2(+11%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Enanta Pharmaceuticals

Jay R. Luly

Jay R. Luly

President, Chief Executive Officer and Director
Brendan Luu

Brendan Luu

Senior Vice President, Business Development
Paul J. Mellett

Paul J. Mellett

Senior Vice President, Finance & Administration and Chief Financial Officer
Show more

Enanta Pharmaceuticals Office Locations

Enanta Pharmaceuticals has an office in Watertown
Watertown, MA, US (HQ)
500 Arsenal St
Watertown, MA, US
400 Talcott Ave
Show all (2)

Enanta Pharmaceuticals Financials and Metrics

Enanta Pharmaceuticals Revenue

Enanta Pharmaceuticals's revenue was reported to be $97.07 m in FY, 2021
USD

Net income (Q2, 2022)

(33.6m)

Market capitalization (29-Jul-2022)

1.1b

Closing stock price (29-Jul-2022)

55.2
Enanta Pharmaceuticals's current market capitalization is $1.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2021

Revenue

32.1m47.7m160.9m88.3m102.8m206.6m205.2m97.1m

Revenue growth, %

49%237%(45%)

General and administrative expense

6.2m10.0m13.5m17.0m20.7m23.4m26.2m32.5m

R&D expense

16.8m18.7m23.2m40.5m57.5m94.9m142.2m174.1m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022

Revenue

1.2m1.6m893.0k2.2m42.1m77.5m57.4m11.6m48.4m13.0m14.0m10.4m9.0m7.5m38.1m44.0m57.3m69.9m39.6m44.4m52.6m27.6m18.7m31.7m20.1m21.6m27.6m

General and administrative expense

1.5m1.8m2.1m2.6m2.6m2.8m3.4m3.6m3.8m4.4m4.3m4.9m5.5m5.2m5.8m5.7m6.1m7.2m6.8m6.2m6.9m6.9m6.8m7.4m8.3m8.5m9.5m

R&D expense

3.7m4.0m4.3m4.7m4.6m4.5m5.4m6.3m9.0m9.1m10.8m12.5m13.0m15.4m18.0m21.5m28.5m34.9m34.2m34.5m32.8m32.6m34.7m36.7m41.5m47.0m48.5m

Operating expense total

5.2m5.8m6.4m7.3m7.2m7.3m8.8m9.9m12.9m13.6m15.1m17.5m18.5m20.6m23.7m27.2m34.6m42.0m40.9m40.6m39.7m39.5m41.5m44.0m49.8m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2021

Cash

8.9m30.7m21.7m16.6m65.7m63.9m51.2m

Accounts Receivable

808.0k1.7m15.3m12.8m10.6m67.2m51.3m

Prepaid Expenses

1.6m1.6m8.3m3.5m4.5m15.3m

Inventories

9.2m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022

Cash

74.5m18.9m4.4m18.1m26.4m34.1m25.8m19.8m46.2m56.4m24.8m20.6m19.2m22.3m68.1m66.9m42.5m74.4m106.0m94.2m27.6m74.3m99.9m55.1m77.1m4.6m

Accounts Receivable

669.0k876.0k279.0k998.0k399.0k76.6m7.1m11.7m17.9m13.0m14.0m10.4m9.0m7.5m23.1m44.0m57.3m69.9m39.6m44.4m52.6m27.6m18.7m31.7m20.1m21.6m

Prepaid Expenses

1.1m1.5m1.3m2.0m2.0m1.2m2.2m3.5m8.5m7.7m8.2m4.3m6.1m6.6m4.1m4.9m9.4m7.6m14.1m17.6m14.2m19.8m24.7m28.0m32.1m12.1m

Current Assets

111.7m97.9m94.4m99.3m111.7m185.1m177.8m172.6m209.0m242.7m241.8m224.1m190.6m206.1m247.6m305.7m339.9m423.3m423.8m451.3m440.5m402.7m413.4m445.9m428.2m321.2m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Net Income

9.6m34.4m79.0m21.7m17.7m72.0m46.4m(36.2m)(79.0m)

Depreciation and Amortization

221.0k352.0k639.0k1.7m2.1m2.5m3.3m3.6m3.3m

Accounts Payable

115.0k399.0k(543.0k)1.5m633.0k1.3m1.8m(883.0k)3.8m

Cash From Operating Activities

10.7m20.2m76.7m35.8m52.7m29.2m71.4m7.1m(70.0m)
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022

Net Income

18.2m14.1m(5.4m)(10.6m)39.5m42.0m70.8m73.2m26.2m24.5m23.5m(5.0m)(10.4m)(18.8m)11.7m24.2m44.5m26.0m30.2m37.2m13.4m7.4m(6.8m)(8.3m)(30.4m)(54.4m)(30.1m)(63.7m)

Depreciation and Amortization

87.0k148.0k75.0k154.0k242.0k129.0k270.0k435.0k339.0k772.0k1.2m493.0k1.0m1.6m587.0k1.2m1.9m680.0k1.5m2.4m904.0k1.8m2.7m871.0k1.7m2.5m780.0k1.6m

Accounts Payable

(469.0k)(620.0k)(648.0k)316.0k(190.0k)(1.3m)488.0k(332.0k)149.0k1.2m677.0k(1.3m)688.0k2.7m(129.0k)565.0k1.4m124.0k2.9m1.6m(179.0k)(731.0k)(672.0k)575.0k15.0k195.0k(1.7m)(3.5m)

Cash From Operating Activities

19.1m13.2m(5.9m)(10.0m)25.1m(5.6m)93.3m79.0m30.0m40.0m37.9m3.1m143.0k(4.7m)4.4m(3.2m)879.0k30.3m60.3m62.9m12.4m27.0m22.5m(14.9m)(19.5m)(49.0m)(13.3m)(39.6m)
show all
USDQ2, 2013

Financial Leverage

1.1 x
Show all financial metrics

Enanta Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

Learn more about our premium products
SecurityScorecard logo

Enanta Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Enanta Pharmaceuticals Online and Social Media Presence

Enanta Pharmaceuticals's Trends

Embed Graph

Enanta Pharmaceuticals Company Culture

  • Overall Culture

    F

    43/100

  • CEO Rating

    F

    10/100

  • Compensation

    A+

    100/100

Learn more on Comparably

 Enanta Pharmaceuticals Frequently Asked Questions

  • When was Enanta Pharmaceuticals founded?

    Enanta Pharmaceuticals was founded in 1998.

  • Who are Enanta Pharmaceuticals key executives?

    Enanta Pharmaceuticals's key executives are Jay R. Luly, Brendan Luu and Paul J. Mellett.

  • How many employees does Enanta Pharmaceuticals have?

    Enanta Pharmaceuticals has 132 employees.

  • What is Enanta Pharmaceuticals revenue?

    Latest Enanta Pharmaceuticals annual revenue is $97.1 m.

  • What is Enanta Pharmaceuticals revenue per employee?

    Latest Enanta Pharmaceuticals revenue per employee is $735.4 k.

  • Who are Enanta Pharmaceuticals competitors?

    Competitors of Enanta Pharmaceuticals include Aligos Therapeutics, Mcneil and Bio Farma.

  • Where is Enanta Pharmaceuticals headquarters?

    Enanta Pharmaceuticals headquarters is located at 500 Arsenal St, Watertown.

  • Where are Enanta Pharmaceuticals offices?

    Enanta Pharmaceuticals has an office in Watertown.

  • How many offices does Enanta Pharmaceuticals have?

    Enanta Pharmaceuticals has 2 offices.